Intrinsiqs

Is Enliven Therapeutics, Inc. overvalued?

Enliven Therapeutics, Inc. (ELVN) — key valuation metrics and fundamentals.

No verdict
Price
$44.75
Fair value
—
Current P/E
—
Normal P/E
—
Market cap
$3.20B
Dividend yield
0.0%
Return on equity
-18.5%
Sector
Healthcare

See the full interactive analysis →

Fair value compares ELVN's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 24 Sep 2026.